Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CAR-T Drugs Break Ground For Stem Cell Therapies In CNS, Says Brainstorm CEO

Executive Summary

Brainstorm’s president and CEO Chaim Lebovits talks to Scrip about the company’s progress with personalized stem cell therapy NurOwn in ALS and what the future holds for cell therapy options in neurology.

You may also be interested in...



Pfizer Exits Early Neuroscience, But M&A Could Allow Later Re-Entry

Pfizer is abandoning research to find new drugs for Alzheimer’s and Parkinson’s disease, realizing that finding treatments for the diseases is very tough - but M&A could allow an eventual return, analysts say.

Dendreon seeks Chapter 11 bankruptcy as $620m debt looms

Dendreon said late on 9 November that it has reached an agreement with certain holders of its convertible senior notes due in 2016 to seek Chapter 11 bankruptcy so that it can reorganize, sell the company or dispose of its assets to manage $620m in debt that must be repaid in 14 months.

Snapshot: July Highlights

A selection of articles you might have missed from July 2020, including exclusive interviews with industry leaders and a review of Q2 financing statistics.

Related Companies

UsernamePublicRestriction

Register

ID1131690

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel